debate: is cr and mrd negativity still required in the era of novel agents? - no
Published 8 years ago • 283 plays • Length 16:26Download video MP4
Download video MP3
Similar videos
-
10:19
myeloma debate: is mrd ready for prime time? - no
-
13:55
debate: optimal approach for the management of cll patients with del(17p) - novel agents
-
21:09
minimal residual disease (mrd) in cll: is it clinically relevant?
-
9:07
debate: should consolidation and minimal residual disease testing be used? - no
-
21:18
myeloma debate: is mrd ready for prime time? - yes
-
14:14
debate: is mrd the new primary goal for multiple myeloma treatment? - no
-
9:11
debate: should consolidation and minimal residual disease testing be used? - yes
-
40:20
mi 423 direct vs indirect action
-
44:17
multi-omics in health and disease (welcome and workshop rationale)
-
46:30
hhv8 negative imcd session
-
52:52
post comy-asco-eha round table - antibody-drug conjugates in rrmm
-
3:17
what does it mean to be mrd negative?
-
16:08
debate: is mrd the new primary goal for multiple myeloma treatment? - yes
-
22:47
the sequencing of novel agents: does it matter?
-
24:17
combination of novel agents in cll: is this the final answer?
-
13:07
debate: mrd, ready for primetime? - no
-
12:26
debate: mrd, ready for primetime? - yes
-
20:13
debate: hypomethylating agents are appropriate in lower-risk mds - only use with caution
-
13:10
debate: is transplant a necessity or a choice for myeloma patients? - yes
-
20:21
novel agents in elderly cll patients: should the approach be different?
-
16:20
molecular mechanisms of mcl and their targeting with novel agents
-
19:41
multiple myeloma: minimal residual disease